Skip to main content
Premium Trial:

Request an Annual Quote

Cypress Acquires Personalized Medicine Technology from Cellatope

NEW YORK (GenomeWeb News) – Cypress Bioscience has acquired Cellatope's technology platform for diagnosing and monitoring autoimmune disorders, such as lupus, for up to $5 million.

San Diego-based Cypress said that the technology platform uses cell-bound complement activation products for diagnosis and monitoring of response to treatment. It was developed by researchers at the Lupus center for Excellence at the University of Pittsburgh to evaluate cell-bound fragments of activated complement proteins and their utility in diagnosis and monitoring of lupus patients.

Cypress intends to complete development of the system and offer personalized medicine services to lupus patients. The firm already sells tests for therapeutic monitoring, diagnosis, and prognosis of patients with rheumatoid arthritis.

Cypress paid $2 million in cash to Cellatope for the CB-CAP technology and will make an additional $3 million potential milestone payment based on commercial development of the technology for lupus monitoring.

In connection with the acquisition, Cypress will assume a license from the University of Pittsburgh.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.